Nucleic acid-based therapeutics for glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Recurrent glioblastoma multiforme (GBM) lacks effective treatments, necessitating novel therapeutic strategies.
• Nucleic acid-based therapeutics provide a promising avenue for developing targeted treatments against malignant diseases like GBM.

Purpose of the Study:

• To review current preclinical and clinical research on nucleic acid therapeutics for GBM.
• To discuss various nucleic acid therapeutic approaches and their delivery vectors for GBM treatment.

Main Methods:

• Review of preclinical and clinical studies on antitumoral nucleic acids for GBM.
• Analysis of gene therapy, RNA interference, and double-stranded RNA delivery strategies.
• Evaluation of viral (non-replicating, oncolytic) and non-viral (polycation, cationic lipid) vectors for nucleic acid delivery.

Main Results:

• Nucleic acid therapeutics, including gene therapy and RNA interference, show potential for GBM treatment.
• Targeted delivery of antitumoral double-stranded RNA is being investigated.
• Various viral and non-viral vectors are being explored for efficient nucleic acid delivery in GBM.

Conclusions:

• Nucleic acid-based therapies represent a viable and customizable treatment option for recurrent GBM.
• Further research into optimizing nucleic acid therapies and delivery systems is crucial for clinical translation in GBM treatment.